To date one of the most discussed problems in the context of psoriasis is the possibility of correlation between the psoriatic process, considering its systemic nature, and the risk of cancer developing. Such interrelation can be caused both by systemic chronic inflammatory process and by methods of therapy. The purpose of this literature review is to assess the risk of developing malignant neoplasms of various organs and systems, as well as the factors that determine it, in patients with psoriasis in comparison with the general population. The mechanisms of action as well as early and remote side effects of the current treatment are described. The literature data on the risk of their carcinogenic effects are presented. The results of studies of a number of other factors acting as possible initiators of carcinogenesis in patients with psoriasis are highlighted, among them: the presence of a systemic inflammatory reaction, the severity and duration of the course of the disease, and also the comorbid states.

No abstract

The relevance of studying psoriasis and its treatment is conditioned by the ever increasing incidence of this condition and frequency of its severe forms. The recent studies on the complications of both psoriasis itself and its treatment have demonstrated the increased risk of associated carcinogenesis. The analysis and systematization of information accumulated to date gives evidence of the relationship between the development of cancer and the application of modern methods for the treatment of psoriasis Moreover, the available data suggest the enhanced risk of cancer in the patients suffering from this disease compared with that in the general population.

Psoriasis is a systemic chronic inflammatory disease that affects in the first place the skin and occurs in 1-5% of the general population. The treatment of the patients presenting with this condition implies the application of the topical agent and biological preparations as well as phototherapy and systemic therapy. The patients suffering severe forms of psoriasis in whom systemic immunosuppressive therapy does not yield the desired effect are in need of the treatment with biological preparations. The use of the inhibitors of tumour necrosis factor-alpha produces the insufficient effect even in the case of the positive response, i.e. the psoriasis area and severity index (PASI) of approximately 50 scores (PASI 50). This article presents the results of the application of photodynamic therapy (PDT) for the treatment of 8 patients treated with the inhibitors of tumour necrosis factor-alpha in whom the PASI value of 50 was achieved within the first week after the onset of the treatment. In all these patients, a course of photodynamic therapy consisting of 2-3 procedures made it possible to increase the PASI values to 75 and even 100 scores. It is concluded that the patients showing positive but insufficient effect of biological therapy (PASI 50) need to be prescribed a course of photodynamic treatment in order to enhance the effectiveness of the biological therapeutic factors.

ФГБу дпо «центральная государственная медицинская академия» управление делами президента российской Федерации, Москва, россия, 121359; 2 Бу хМао-Югры «ханты-Мансийский клинический кожно-венерологический диспансер», ханты-Мансийск, россия, 628012 Цель исследования-изучить эффективность 2% крема сертаконазола в сравнении с 1% кремом клотримазола и 1% кремом тербинафина у пациентов с микозом стоп. Материал и методы. обследованы и пролечены 76 пациентов с подтвержденным (микроскопия, бактериологический посев) диагнозом микоз стоп. Мониторинг пациентов соответствовал стандартам при данном заболевании и включал объективные методы исследования: микроскопия/бак.посев, клинические методы индекс Vas (эритема, инфильтрация, десквамация, трещины, зуд, болезненность) и индекс диКЖ. результаты. Было показано, что применение 2% крема сертаконазола залаин позволяет достигнуть клинического и лабораторного излечения у 100% пациентов вне зависимости от вида гриба. положительная динамика со стороны кожного процесса сопровождается улучшением качества жизни пациентов. отдаленные результаты наблюдений (6 мес) показали отсутствие рецидивов. Выводы. сертаконазол залаин в виде 2% крема является высокоэффективным топическим средством в лечении и профилактике рецидивов микоза стоп вне зависимости от вида возбудителя, в том числе при наличии устойчивых к ряду противогрибковых средств штаммов грибов. Ключевые слова: микоз гладкой кожи, сертаконазол 2% крем, залаин, клотримазол, тербинафин, лечение, профилактика рецидивов. Evaluation of the effectiveness of the sertaconazole cream in patients with tinea pedis l.s. krugloVa, E.s. poNiCh, a.M. BaBushkiN Central state Medical academy, russian presidential Executive office, Moscow, russia, 121359; khanty-Mansiysk Clinical Dermatovenerologic Dispensary, khanty-Mansiysk autonomous District, Yugra, russia, 628012 Objective. The study is aimed at assessing the effectiveness of 2% sertaconazole cream compared to 1% clotrimazole cream and 1% terbinafine cream in patients with tinea pedis. Material and methods. We examined and treated 76 patients with confirmed (microscopy, bacteriological test) diagnosis of tinea pedis. Monitoring of patients complied with the standards appropriate for this disease and included objective research methods: microscopy/bacterial inoculation, clinical methods, Vas index (erythema, infiltration, desquamation, cracks, itching, tenderness) and DlQi index. Results. it has been shown that application of 2% sertaconazole cream results in clinical and laboratory cure in 100% of the patients, regardless of the type of fungus. positive dynamics of the skin process is accompanied by improvement of the quality of life of patients. long-term follow-up results (6 months) showed no recurrence. Conclusions. sertaconazole in the form of 2% topical cream is highly effective topical tool in treatment and prevention of recurrences of tinea pedis, regardless of the type of pathogen, including fungal strains resistant to some antifungal agents.